Published in Blood Weekly, September 19th, 2002
Taner Demirer and colleagues at Ankara Numune Research Hospital and other institutions in Ankara, Gazi, Mersin, and Hacettepe "evaluated the effect of post-transplant recombinant human granulocyte colony-stimulating factor (rhG-CSF) administration on the parameters of peritransplant morbidity."
Treatment with rhG-CSF hastened hematological recovery and attenuated peritransplant morbidity, Demirer and coauthors found.
The researchers compared transplant...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.